Platinum drugs in the treatment of non-small-cell lung cancer

British Journal of Cancer

Volumn 87, Issue 8, 2002, Pages 825-833

  Cosaert, J ^a   Quoix, E ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

BBR3464; Carboplatin; Cisplatin; Non small cell lung cancer; Oxaliplatin; ZD0473

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; BBR 3464; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; VINDESINE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; HUMAN; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 0037037386     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600540     Document Type: Review

References (115)

1. Abratt RP (1995) Current chemotherapy of advanced non-small cell lung cancer. Anticancer Drugs 6(Suppl 6): 15-18
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626
3. Alberola V, Camps C, Provencia M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jimenez U, Ganzalez-Larriba JL, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ (2001) Cisplatin/Gemcitabine (CG) vs. Cisplatin/Gemcitabine/Vinorelbine (CGV) vs. Sequential Doublets of Gemcitabine/Vinorelbine followed by Ifosfamide/Vinorelbine (GV/IV) in advanced Non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial (GEPC/98-02) (abstract). Proc Am Soc Clin Oncol 20: A1229
4. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small cell Lung Cancer. Br J Cancer 83: 447-453
5. Bahl A, Falk S (2001) Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?. Br J Cancer 84: 1143-1145
6. Bakowski MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: A reappraisal and a look to the future. Cancer Treat Rev 10: 159-172
7. Bardet E, Riviere A, Charloux A, Spaeth D, Ducolone A, Le Groumellec A, Pellae-Cosset B, Henry-Amar M, Douillard JY (1997) A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis. Int J Radiat Oncol Biol Phys 38: 163-168
8. Bissett D, Kunkeler L, Zwanenburg L, Paul J, Gray C, Swan IR, Kerr DJ, Kaye SB (1990) Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 62: 655-659
9. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602-1613
10. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19: 1734-1742
11. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM, Vogt-Moykopf I (1992) New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102-1110
12. Bunn Jr PA (1989a) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16: 10-21
13. Bunn Jr PA (1989b) Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16: 27-33
14. Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4: 1087-1100
15. Bunn Jr PA, Vokes EE, Langer CJ, Schiller JH (1998) An update on North American randomized studies in non-small cell lung cancer. Semin Oncol 25: 2-10
16. Calvert PM, Highley MS, Hughes AN, Plummer ER, Azzabi AST, Verrill MW, Camboni MG, Verdie, Bernareggi A, Zuchetti M, Robinson AM, Carmichael J, Calvert AH (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors (abstract/poster no. 333). Clin Cancer Res 5: (Suppl): 3796
17. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
18. Canpolat C, Pearson P, Jaffe N (1994) Cisplatin-associated hemolytic uremic syndrome. Cancer 74: 3059-3062
19. Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R, Canal P (1995) Prediction of carboplatin clearance from morphological and biological patient characteristics (In French). Bull Cancer 82: 946-953
20. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4-11
21. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, iphosphamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530
22. Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Costanzo F, Buzzi F, Fornari G, Santi E, Ballatori E (1990) A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): A study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 26: 52-56
23. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17: 3188-3194
24. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol 5: 37-42
25. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20: 247-253
26. Deslauriers J, Gregoire J (2000) Surgical therapy of early non-small cell lung cancer. Chest 117: 104S-109S
27. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei IIIEF, Green MR (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945
28. Douillard J, Cosaert J, Barbarot V (2001a) Phase I trial of ZD0473 in combination with Vinorelbine for Patients with advanced cancer (abstract 274). Eur J Cancer 37(Suppl 6): S77
29. Douillard JY, Lerouge D, Monnier A, Bennouna J, Haller AM, Sun XS, Assouline D, Grau B, Riviere A (2001b) Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: A multicentre phase II study. Br J Cancer 84: 1179-1184
30. Dufour P, Bergerat JP, Eber M, Renaud P, Karcher V, Giron C, Leroy MJ, Oberling F (1990) Cisplatin-induced anemia: A potential interference with iron metabolism at erythroid progenitors level. Anticancer Drugs 1: 49-54
31. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Mueller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 16: 622-634
32. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W (1986) Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037-1043
33. Elliott JA, Ahmedzai S, Hole D, Dorward AJ, Stevenson RD, Kaye SB, Banham SW, Stack BH, Calman KC (1984) Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study. Eur J Cancer Clin Oncol 20: 1025-1032
34. Fauser AA, Fellhauer M, Hoffmann M, Link H, Schlimok G, Gralla RJ (1999) Guidelines for anti-emetic therapy: Acute emesis. Eur J Cancer 35: 361-370
35. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE (1995) Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 13: 323-332
36. Fink D, Howell S (eds) (2000) How does cisplatin kill cells. In Platinum-Based Drugs in Cancer Therapy, Kelland L, Farrell N (eds) pp 149-167 Totowa, NJ: Humana Press Inc.
37. Fossella FV (1999a) Docetaxel in the treatment of non-small cell lung cancer: Review of single-agent trials. Semin Oncol 26: 17-23; discussion 41-42
38. Fossella FV (1999b) Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol 26: 4-8
39. Franciosi V, Barbieri R, Vasini G, Cacciani GC, Capra R, Cuomo A, Greco F, Bozzetti C, Cascinu S (2001) A feasible combination of gemcitabine and oxaliplatin (GEM-OXAL) in patients with advanced non-small cell lung cancer. Preliminary results of a phase II study. Proc Am Soc Clin Oncol 20: 263b (abstract 2804)
40. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699
41. Gatzemeier U, Heckmayr M, Hossfeld DK, Zschaber R, Achterrath W, Lenaz L (1990a) Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol 26: 369-372
42. Gatzemeier U, Heckmayr M, Neuhauss R, Hossfeld D, Achterrath W, Lenaz L (1990b) Phase II studies with carboplatin in non-small cell lung cancer. Semin Oncol 17: 25-31
43. Gatzemeier U, Rosell R, Betticher D, Keppler U, Macha HN, Pirker R, Berthet P, Brau JL, Bogaerts J, Gallant G (1999) Randomized Pan-European Trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (abstract). Eur J Cancer 35(Suppl 4): 973
44. Gatzemeier U, Twelves C, Anthoney DA, Pentheroudakis G, Groth G, Cosaert J (2001) A phase I dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies (abstract 264). Eur J Cancer 37(Suppl 6): S74
45. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 3390-3399
46. Georgoulias V, Ardavanes A, Agelidon M, Papadakis E, Rapti A, Palamidas P, Toubis M, Kouroussis C, Polyzos A, Syrigos K (2002) Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC) (abstract 1163). Proc Am Soc Clin Oncol 20: 291a
47. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 357: 1478-1484
48. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59(Suppl 4): 9-17; discussion 37-38
49. Ginopoulos P, Spyropoulos K, Kardamakis D, Dougenis D, Onyenadum A, Gogos CH, Solomou E, Chrysanthopoulos K (1997) Advanced non-small cell lung cancer chemotherapy: A randomized trial of two active regimens (MVP and PE). Cancer Lett 119: 241-247
50. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422
51. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17: 2971-2994
52. Grant SC, Kris MG (1995) New antineoplastic agents in lung cancer 1988-1993. Cancer Treat Res 72: 323-347
53. Hamilton CR, Bliss JM, Horwich A (1989) The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 25: 185-189
54. Hoctin-Boes G, Cosaert J, Koehler M, Smith M (2001) Safety profile of ZD0473 in phase II trials of patients with advanced cancers (poster). Br Cancer Res Meeting July 2001
55. Hoffman PC, Mauer AM, Otterson GA, Rudin CM, Villalona MA, Golomb HM, Wade JL, Lanzanotti VJ, Ansari RH, Szeto LL, Vokes EE (2001) Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 20: A2852, p. 275b
56. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley, JA, Abrams M, Kelland LR (1998a) Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des 13: 1-18
57. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998b) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77: 366-373
58. Huisman C, Smit EF, Giaccone G, Postmus PE (2000) Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review. J Clin Oncol 18: 3722-3730
59. Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G (1999) A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 44: 343-348
60. Johnson DH (1995) Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst Monogr 19: 61-63
61. Johnson DH (2000) Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: A historical perspective and the eastern cooperative oncology group experience. Chest 117(Suppl): S133-S137
62. Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A (1997) Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 8: 604-606
63. Judson I, Kelland LR (2000) New developments and approaches in the platinum arena. Drugs 59(Suppl 4): 29-36; discussion 37-38
64. Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, Negoro S, Kusunoki Y, Matui K, Takifuji N (1991) A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68: 714-719
65. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59:(Suppl 4): 1-8; discussion 37-38
66. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218
67. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J, Lecomte J, Cordier R, Dabouis G (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol 7: 1087-1092
68. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8: 1556-1562
69. Kreisman H, Goutsou M, Modeas C, Graziano SL, Costanza ME, Green MR (1990) Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: A Cancer and Leukemia Group B study. Eur J Cancer 26: 1057-1060.
70. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417-423
71. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367
72. Lilenbaum RC, Herndon J, List M, Desch C, Watson D, Holland J, Weeks JC, Green MR (2002) Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomised trial of efficacy, quality of life (QOL) and cost-effectiveness (abstract 2). Proc Am Soc Clin Oncol 20: la
73. Lilenbaum RC, Langenberg P, Dickersin K (1998) Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: A meta-analysis of response, toxicity, and survival. Cancer 82: 116-126
74. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9: 13-21
75. Marino P, Preatoni A, Cantoni A, Buccheri G (1995) Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: A quality and meta-analysis study. Lung Cancer 13: 1-12
76. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244
77. Miller VA, Kris MG (2000) Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27: 3-10
78. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, Soulie P, Armand JP, Cvitkovic E, de Cremoux H (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 34: 1124-1127
79. Monnet I, de Cremoux H, Soulié P, Saltiel-Voisin S, Bekkrada M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E (2002) Oxaliplatin plus vinorelbine in advanced-non-small-cell lung cancer: Final results of a multicenter phase II study. Ann Oncol 13: 103-107
80. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717
81. Natale RB (1998) Experience with new chemotherapeutic agents in non-small cell lung cancer. Chest 113(Suppl): S32-S39
82. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909
83. O'Dwyer PJ, Stevenson JP, Redlinger M, Sun W, Giantonio B, Hahn S, Algazy K, Burnite M, Koehler M (2001) Phase I trial of the novel platinum analogue ZD0473 in combination with gemcitabine (GEM) for patients with advanced cancers (abstract). Proc Am Soc Clin Oncol 20: A1354, p. 339a
84. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam Jr JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn Jr PA (2000) Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Sur 119: 429-439
85. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92: 1074-1080
86. Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR (1997) cis-amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 3: 2063-2074
87. Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fossella F, Kaukel E, Mattson K, Millward M, Kim YS, Gamza F, Berilie J, Belani CP (2001) A multicenter, randomised phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (abstract 1252). Proc Am Soc Clin Oncol 20: 314a
88. Rosell R, Felip E (2001) Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 28(Suppl 14): S37-S44
89. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153-158
90. Rosso R, Salvati F, Ardizzoni A, Gallo Curcio C, Rubagotti A, Belli M, Castagneto B, Fusco V, Sassi M, Ferrara G (1990) Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force. Cancer 66: 130-134
91. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J (2000) A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27: 145-157
92. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam Jr JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21: 1-6
93. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86: 673-680
94. Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable) (Cochrane Review). In The Cochrane Library, 1, 2001. Oxford: Update Software
95. Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH (1985) Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3: 72-79
96. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122-130
97. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Bianco A, Boni C, Marangolo M, Failla G, Adamo V, Altavilla G, Ceribelli A Clerici M, Di Costanzo F, Frontini L, Tonato M on behalf of the Italian Lung Cancer Project (2001) Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer (abstract 1227). Proc Am Soc Clin Oncol 20: 308a
98. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10(Suppl 1): S263-S270
99. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98
100. Sederholm C (2002) Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 20: 291a (abstract 1162)
101. Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Vigano L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S (2000) Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 11: 977-983
102. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103
103. Socinski MA, Langer CJ (1999) Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. Semin Oncol 26: 51-61; discussion 71-72
104. Soria JC, Brisgand D, Le Chevalier T (2001) Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12: 1667-1670
105. Souquet JP, Tan EH, Pereira JR, Klaveren RV (2001) GLOB1, A prospective randomised phase III trial comparing Vinorelbine and Cisplatin (NP) versus Vinorelbine, ifosfamide and cisplatin (NIP) in metastatic NSCLC patients (PTS): A patient's benefit analysis. Proc Am Soc Clin Oncol 20: A1337 (abstract)
106. Splinter TA (1990) Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 26: 1093-1099
107. Splinter TA, Sahmoud T, Festen J, van Zandwijk N, Sorenson S, Clerico M, Burghouts J, Dautzenberg B, Kho GS, Kirkpatrick A, Giaccone G (1996) Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: A randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14: 127-134
108. Stephens RJ, Fairlamb D, Gower N, Maslove L, Milroy R, Napp V, Peake MD, Rudd RM, Spiro S, Thorpe H, Waller D (2002) The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting (abstract 1161). Proc Am Soc Clin Oncol 20: 291a
109. Trigo JM, Beale P, Judson IR, Raynaud F, Rees C, Milan D, Wolf L, Walker R, Hanwell J, Giandomenico C (1999) Phase I and Pharmacokinetic (PK) Study of Cis-Amminedichloro (2-Methylpyridine) Platinum (II) (ZD0473), a Novel Sterically Hindered Platinum Complex, in Patients (pts) with Advanced Solid Malignancies. Proc Am Soc Clin Oncol 18: A648 (abstract)
110. Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G, Pizzi G, Torretta A, Veronesi A, Gobitti C (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24: 11-15
111. Van Meerbeeck JP, Smit EF, Lianes P, Schramel F, Lenz M, Debruyne C, Giaccone G (EORTC Lung Cancer Groupe) (2001) A EORTC randomised phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 308a (abstract 1228)
112. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18: 1351-1359
113. Wood PA, Hrushesky WJ (1995) Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 95: 1650-1659
114. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16: 2459-2465
115. Zatloukal P, Petruzelka L, Zemanova M, Kolek V, Grygarkova I, Sixtova D, Roubec J, Horenkova E, Kuta M, Havel L, Prusa P, Novakova L Czech Lung Cancer Cooperative Group (2001) Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients (Pts) with non-small cell lung cancer (NSCLC) stage IIIb and IV: And interim analysis of a randomized trial. Proc Am Soc Clin Oncol 20: A1343 (abstract), p. 337a